More evidence in quest to repurpose cancer drugs for Alzheimer's disease

July 27, 2016

An FDA approved drug to treat renal cell carcinoma appears to reduce levels of a toxic brain protein linked to dementia in Alzheimer's and Parkinson's diseases when given to animals. This finding is the latest from Georgetown University Medical Center's Translational Neurotherapeutics Program (TNP) examining tyrosine kinase inhibitors in the treatment of neurodegenerative diseases.

The study, to be presented at the annual Alzheimer's Association International Conference in Toronto, found that the drug pazopanib decreases levels of phosphorylated Tau (p-Tau) in animal models genetically engineered to produce human mutant tau throughout their brains.

The TNP lab previously demonstrated in animal models that tau is a critical part of the " system," in cells allowing them to clear accumulated toxic proteins. In humans, p-Tau describes tau that has been abnormally modified, leaving it unable to do its job.

"Our lab has shown that functional tau is required for the clearance of , which accumulates in sticky clumps called plaques. If tau stops functioning, the amyloid beta accumulation leads to cell death," explains Monica Javidnia, a pharmacology doctoral candidate at GUMC. "When tau is abnormally modified, it accumulates within neurons forming sticky tangles, and the when the cell dies, it and the amyloid beta spill out into the brain. These are the plaques and tangles that are the hallmark of Alzheimer's disease." P-tau is also involved in other neurodegenerative diseases.

Previous research from the TNP has shown that when tyrosine kinases are inhibited, the garbage disposal system begins working, allowing cells to once again clear toxic proteins. Pazopanib is a known inhibitor.

The TNP, led by Charbel Moussa, MD, PhD, has identified several tyrosine kinase, which appear to play a role in neurodegeneration, protein clearance and inflammation. This work has led to clinical trials with the cancer drug nilotinib in both Parkinson's and Alzheimer's disease set to begin this summer. (Moussa is listed as an inventor on a patent application that Georgetown University filed related to nilotinib and the use of other tyrosine kinase inhibitors for the treatment of .)

As Javidnia explains, there are two schools of thought in the Alzheimer's field as to the main culprit of the disease—tau or amyloid beta.

"Work from our lab and other groups shows tau pathology preceding amyloid beta. We believe tau is mainly responsible for dementia and exacerbates A-beta pathology," she says. "However, we are also studying the effects of pazopanib on amyloid beta to create a better understanding of how it works and what diseases it could potentially be used to treat."

Javidnia says analysis in this study shows pazopanib penetrates the mice's blood-brain barrier when given the equivalent of half of dose given for treatment. Following treatment, the animal models showed significant decreases in levels of phosphorylated tau.

"In addition, the drug was safe and well-tolerated," Javidnia says. "Our next work will focus on the individual receptors pazopanib targets to better understand their role in protein clearance and inflammation."

Explore further: Genetically engineered mice suggest new model for how Alzheimer's causes dementia

More information: Poster # 8677: Abstract: Pazopanib Is a Potential Therapeutic for Tauopathies

Related Stories

Genetically engineered mice suggest new model for how Alzheimer's causes dementia

July 4, 2016
Using a novel, newly developed mouse model that mimics the development of Alzheimer's disease in humans, Johns Hopkins researchers say they have been able to determine that a one-two punch of major biological "insults" must ...

Tau, not amyloid-beta, triggers neuronal death process in Alzheimer's

October 31, 2014
New research points to tau, not amyloid-beta (Abeta) plaque, as the seminal event that spurs neuron death in disorders such as Alzheimer's disease. The finding, which dramatically alters the prevailing theory of Alzheimer's ...

Using tau imaging as diagnostic marker for Alzheimer disease

July 25, 2016
The accumulation of β-Amyloid (Αβ) and tau proteins in the brain is hallmark pathology for Alzheimer disease. Recently developed positron emission tomography (PET) tracers, including [18F]-AV-1451, bind to tau in neurofibrillary ...

Scientists use immunotherapy to reduce memory problems with Alzheimer's disease

March 25, 2015
A new study from the University of Texas Medical Branch at Galveston has revealed that a single dose of an immunotherapy reverses memory problems in an animal model of Alzheimer's disease. The article appears in the March ...

PET points to tau protein as leading culprit in Alzheimer's

June 13, 2016
Alzheimer's is a devastating and incurable disease marked by beta-amyloid and tau protein aggregations in the brain, yet the direct relationship between these proteins and neurodegeneration has remained a mystery. New molecular ...

Toxic Alzheimer's protein spreads through brain via extracellular space

July 18, 2016
A toxic Alzheimer's protein can spread through the brain—jumping from one neuron to another—via the extracellular space that surrounds the brain's neurons, suggests new research from Columbia University Medical Center.

Recommended for you

Lifestyle changes to stave off Alzheimer's? Hints, no proof

July 20, 2017
There are no proven ways to stave off Alzheimer's, but a new report raises the prospect that avoiding nine key risks starting in childhood just might delay or even prevent about a third of dementia cases around the world.

Steering an enzyme's 'scissors' shows potential for stopping Alzheimer's disease

July 19, 2017
The old real estate adage about "location, location, location" might also apply to the biochemical genesis of Alzheimer's disease, according to new research from the University of British Columbia.

Brain scans may change care for some people with memory loss

July 19, 2017
Does it really take an expensive brain scan to diagnose Alzheimer's? Not everybody needs one but new research suggests that for a surprising number of patients whose memory problems are hard to pin down, PET scans may lead ...

Can poor sleep boost odds for Alzheimer's?

July 18, 2017
(HealthDay)— Breathing problems during sleep may signal an increased risk for Alzheimer's disease, a trio of studies suggests.

Hearing is believing: Speech may be a clue to mental decline

July 17, 2017
Your speech may, um, help reveal if you're uh ... developing thinking problems. More pauses, filler words and other verbal changes might be an early sign of mental decline, which can lead to Alzheimer's disease, a study suggests.

Bacteria found in Alzheimer's brains

July 17, 2017
Researchers in the UK have used DNA sequencing to examine bacteria in post-mortem brains from patients with Alzheimer's disease. Their findings suggest increased bacterial populations and different proportions of specific ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.